Description
SWOT ANALYSIS OF EISAI
Eisai
Parent Company
Eisai
Category
Pharmaceutical
Sector
Healthcare
Tagline/ Slogan
Striving to be human healthcare company
USP
Its research based human healthcare ompany
STP
Segment
CNS, oncology, rheumatism, gastrointestinal diseases
Target Group
Healthcare professionals & doctors offering solutions in these segments
They give first thought to the patients & their families and aim to Positioning increase the benefits provided by healthcare
SWOT Analysis
1. Their blockbuster drug Aricept is major drug in Alzheimer’s disease 2. Eisai has identified multiple pathways to offer treatment to cancer patients 3. Strong product pipeline 4. Majority of drugs in maturing stage Strength 5. Over 11,560 well trained employees
1. Limited presence in emerging market 2. Limited number of bestseller drugs. Weakness 3. Patent expiration in U.S has adverse affect on sales
1. They can increase their presence in oncology segment via strategic acquisition 2. Increasing prevalence of chronic diseases such as Alzheimer’s disease Opportunity 3. increasing awareness about healthcare solutions
Threats
1. Growth rate in mature pharmaceutical market is decreasing
2. Natural disasters in Japan 3. Economic slowdown which reduces average spend on healthcare
Competition
1. Takeda pharmaceutical 2. Astrazeneca PLC 3. Astellas pharmaceutical Competitors 4. Teva Pharmaceuticals
doc_497073518.docx
SWOT ANALYSIS OF EISAI
Eisai
Parent Company
Eisai
Category
Pharmaceutical
Sector
Healthcare
Tagline/ Slogan
Striving to be human healthcare company
USP
Its research based human healthcare ompany
STP
Segment
CNS, oncology, rheumatism, gastrointestinal diseases
Target Group
Healthcare professionals & doctors offering solutions in these segments
They give first thought to the patients & their families and aim to Positioning increase the benefits provided by healthcare
SWOT Analysis
1. Their blockbuster drug Aricept is major drug in Alzheimer’s disease 2. Eisai has identified multiple pathways to offer treatment to cancer patients 3. Strong product pipeline 4. Majority of drugs in maturing stage Strength 5. Over 11,560 well trained employees
1. Limited presence in emerging market 2. Limited number of bestseller drugs. Weakness 3. Patent expiration in U.S has adverse affect on sales
1. They can increase their presence in oncology segment via strategic acquisition 2. Increasing prevalence of chronic diseases such as Alzheimer’s disease Opportunity 3. increasing awareness about healthcare solutions
Threats
1. Growth rate in mature pharmaceutical market is decreasing
2. Natural disasters in Japan 3. Economic slowdown which reduces average spend on healthcare
Competition
1. Takeda pharmaceutical 2. Astrazeneca PLC 3. Astellas pharmaceutical Competitors 4. Teva Pharmaceuticals
doc_497073518.docx